Year-end report January 2017 – March 2018
CEO’s comments In January, EQL further strengthened the organization through the appointment of Axel Schörling as the new COO. During recent years, EQL has invested heavily in investment in new drug development and has a time of strong growth ahead. In this context, Axel's competence will play a key role in the company. EQL now has an organization well-equipped for the major investment that has been made and continues. Both during and after the end of the quarter, new products have been approved for sale. Among these, Potassium chloride has already been launched on the Swedish market,